Do analysts prefer AKBA or NNNN?

Akebia Therapeutics presently has a consensus price target of $4.67, indicating a potential upside of 282.51%. Given Akebia Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Akebia Therapeutics is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akebia Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings & valuation, AKBA or NNNN?

Anbio Biotechnology has lower revenue, but higher earnings than Akebia Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Akebia Therapeutics $236.20M 1.39 -$5.34M -$0.08 N/A Anbio Biotechnology $8.65M 164.68 $6.40M N/A N/A

Does the media prefer PAHC or AKBA?

In the previous week, Phibro Animal Health had 3 more articles in the media than Akebia Therapeutics. MarketBeat recorded 5 mentions for Phibro Animal Health and 2 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 1.61 beat Phibro Animal Health's score of 1.27 indicating that Akebia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akebia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to AKBA or AKTS?

In the previous week, Aktis Oncology had 3 more articles in the media than Akebia Therapeutics. MarketBeat recorded 5 mentions for Aktis Oncology and 2 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 1.61 beat Aktis Oncology's score of 0.66 indicating that Akebia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akebia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Aktis Oncology 0 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AKBA or XNCR?

In the previous week, Xencor had 3 more articles in the media than Akebia Therapeutics. MarketBeat recorded 5 mentions for Xencor and 2 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 1.61 beat Xencor's score of 0.88 indicating that Akebia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akebia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Xencor 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Akebia Therapeutics (AKBA) Competitors

$1.22 0.00 (0.00%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$1.23 +0.01 (+0.82%)

As of 07/24/2026 07:34 PM Eastern

Compare

AKBA vs. NNNN, PAHC, AKTS, XNCR, and IMTX

Should you buy Akebia Therapeutics stock or one of its competitors? MarketBeat compares Akebia Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Akebia Therapeutics include Anbio Biotechnology (NNNN), Phibro Animal Health (PAHC), Aktis Oncology (AKTS), Xencor (XNCR), and Immatics (IMTX). These companies are all part of the "pharmaceutical products" industry.

How does Akebia Therapeutics compare to Anbio Biotechnology?

Akebia Therapeutics (NASDAQ:AKBA) and Anbio Biotechnology (NASDAQ:NNNN) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

Anbio Biotechnology has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -8.83%. Anbio Biotechnology's return on equity of 0.00% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akebia Therapeutics	-8.83%	-62.72%	-5.66%
Anbio Biotechnology	N/A	N/A	N/A

Akebia Therapeutics presently has a consensus price target of $4.67, indicating a potential upside of 282.51%. Given Akebia Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Akebia Therapeutics is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akebia Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Anbio Biotechnology has lower revenue, but higher earnings than Akebia Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akebia Therapeutics	$236.20M	1.39	-$5.34M	-$0.08	N/A
Anbio Biotechnology	$8.65M	164.68	$6.40M	N/A	N/A

33.9% of Akebia Therapeutics shares are owned by institutional investors. 4.3% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Akebia Therapeutics has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 5.15, suggesting that its stock price is 415% more volatile than the broader market.

In the previous week, Akebia Therapeutics and Akebia Therapeutics both had 2 articles in the media. Akebia Therapeutics' average media sentiment score of 1.61 beat Anbio Biotechnology's score of 1.43 indicating that Akebia Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Akebia Therapeutics	Very Positive
Anbio Biotechnology	Positive

Summary

Akebia Therapeutics beats Anbio Biotechnology on 7 of the 13 factors compared between the two stocks.

How does Akebia Therapeutics compare to Phibro Animal Health?

Phibro Animal Health (NASDAQ:PAHC) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

Phibro Animal Health currently has a consensus target price of $42.50, suggesting a potential upside of 24.89%. Akebia Therapeutics has a consensus target price of $4.67, suggesting a potential upside of 282.51%. Given Akebia Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Akebia Therapeutics is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Akebia Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Phibro Animal Health had 3 more articles in the media than Akebia Therapeutics. MarketBeat recorded 5 mentions for Phibro Animal Health and 2 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 1.61 beat Phibro Animal Health's score of 1.27 indicating that Akebia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Akebia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Phibro Animal Health has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market.

Phibro Animal Health has a net margin of 6.35% compared to Akebia Therapeutics' net margin of -8.83%. Phibro Animal Health's return on equity of 37.14% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.35%	37.14%	8.57%
Akebia Therapeutics	-8.83%	-62.72%	-5.66%

Phibro Animal Health has higher revenue and earnings than Akebia Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.30B	1.06	$48.26M	$2.33	14.61
Akebia Therapeutics	$236.20M	1.39	-$5.34M	-$0.08	N/A

99.3% of Phibro Animal Health shares are held by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by insiders. Comparatively, 4.3% of Akebia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Phibro Animal Health beats Akebia Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Akebia Therapeutics compare to Aktis Oncology?

Akebia Therapeutics (NASDAQ:AKBA) and Aktis Oncology (NASDAQ:AKTS) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

33.9% of Akebia Therapeutics shares are held by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are held by institutional investors. 4.3% of Akebia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Akebia Therapeutics has higher revenue and earnings than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than Akebia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akebia Therapeutics	$236.20M	1.39	-$5.34M	-$0.08	N/A
Aktis Oncology	$6.50M	196.27	-$63.73M	-$0.38	N/A

Akebia Therapeutics presently has a consensus target price of $4.67, indicating a potential upside of 282.51%. Aktis Oncology has a consensus target price of $34.60, indicating a potential upside of 44.83%. Given Akebia Therapeutics' higher probable upside, equities analysts plainly believe Akebia Therapeutics is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akebia Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Aktis Oncology has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -8.83%. Aktis Oncology's return on equity of 0.00% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akebia Therapeutics	-8.83%	-62.72%	-5.66%
Aktis Oncology	N/A	N/A	N/A

In the previous week, Aktis Oncology had 3 more articles in the media than Akebia Therapeutics. MarketBeat recorded 5 mentions for Aktis Oncology and 2 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 1.61 beat Aktis Oncology's score of 0.66 indicating that Akebia Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akebia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Aktis Oncology	0 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Aktis Oncology beats Akebia Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Akebia Therapeutics compare to Xencor?

Akebia Therapeutics (NASDAQ:AKBA) and Xencor (NASDAQ:XNCR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

33.9% of Akebia Therapeutics shares are owned by institutional investors. 4.3% of Akebia Therapeutics shares are owned by company insiders. Comparatively, 5.1% of Xencor shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Akebia Therapeutics has a net margin of -8.83% compared to Xencor's net margin of -177.10%. Xencor's return on equity of -28.77% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akebia Therapeutics	-8.83%	-62.72%	-5.66%
Xencor	-177.10%	-28.77%	-20.52%

Akebia Therapeutics presently has a consensus price target of $4.67, suggesting a potential upside of 282.51%. Xencor has a consensus price target of $24.25, suggesting a potential upside of 24.74%. Given Akebia Therapeutics' higher probable upside, research analysts clearly believe Akebia Therapeutics is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akebia Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Xencor	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Akebia Therapeutics has higher revenue and earnings than Xencor. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akebia Therapeutics	$236.20M	1.39	-$5.34M	-$0.08	N/A
Xencor	$125.58M	11.48	-$91.92M	-$2.29	N/A

Akebia Therapeutics has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market. Comparatively, Xencor has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market.

In the previous week, Xencor had 3 more articles in the media than Akebia Therapeutics. MarketBeat recorded 5 mentions for Xencor and 2 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 1.61 beat Xencor's score of 0.88 indicating that Akebia Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akebia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Xencor	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Akebia Therapeutics beats Xencor on 8 of the 15 factors compared between the two stocks.

How does Akebia Therapeutics compare to Immatics?

Akebia Therapeutics (NASDAQ:AKBA) and Immatics (NASDAQ:IMTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk.

In the previous week, Akebia Therapeutics had 1 more articles in the media than Immatics. MarketBeat recorded 2 mentions for Akebia Therapeutics and 1 mentions for Immatics. Immatics' average media sentiment score of 1.89 beat Akebia Therapeutics' score of 1.61 indicating that Immatics is being referred to more favorably in the news media.

Company	Overall Sentiment
Akebia Therapeutics	Very Positive
Immatics	Very Positive

33.9% of Akebia Therapeutics shares are held by institutional investors. Comparatively, 64.4% of Immatics shares are held by institutional investors. 4.3% of Akebia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Akebia Therapeutics has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market. Comparatively, Immatics has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market.

Akebia Therapeutics has a net margin of -8.83% compared to Immatics' net margin of -572.35%. Immatics' return on equity of -47.36% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akebia Therapeutics	-8.83%	-62.72%	-5.66%
Immatics	-572.35%	-47.36%	-39.35%

Akebia Therapeutics presently has a consensus price target of $4.67, indicating a potential upside of 282.51%. Immatics has a consensus price target of $20.80, indicating a potential upside of 129.07%. Given Akebia Therapeutics' higher possible upside, equities analysts plainly believe Akebia Therapeutics is more favorable than Immatics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akebia Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Akebia Therapeutics has higher revenue and earnings than Immatics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akebia Therapeutics	$236.20M	1.39	-$5.34M	-$0.08	N/A
Immatics	$54.60M	22.30	-$222.26M	-$1.99	N/A

Summary

Akebia Therapeutics beats Immatics on 8 of the 15 factors compared between the two stocks.

Get Akebia Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKBA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AKBA vs. The Competition

Export

Metric	Akebia Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$327.27M	$3.08B	$7.06B	$12.20B
Dividend Yield	N/A	2.07%	2.67%	9.42%
P/E Ratio	N/A	20.29	27.10	23.63
Price / Sales	1.39	803.57	582.62	111.68
Price / Cash	N/A	27.32	49.81	58.78
Price / Book	10.17	4.13	10.28	6.01
Net Income	-$5.34M	$65.94M	$3.60B	$331.99M
7 Day Performance	-8.96%	-4.16%	-1.27%	-0.63%
1 Month Performance	7.02%	-5.47%	-1.67%	-3.04%
1 Year Performance	-65.73%	9.95%	18.25%	13.30%

Akebia Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AKBA Akebia Therapeutics	2.5596 of 5 stars	$1.22 flat	$4.67 +282.5%	-65.7%	$327.27M	$236.20M	N/A	430	Positive News Gap Down
NNNN Anbio Biotechnology	1.4109 of 5 stars	$9.52 +0.3%	N/A	N/A	$1.37B	$8.65M	N/A	27	Short Interest Decrease Gap Down
PAHC Phibro Animal Health	4.8429 of 5 stars	$33.05 -0.8%	$42.50 +28.6%	+16.6%	$1.35B	$1.50B	14.18	2,475	Positive News
AKTS Aktis Oncology	2.2522 of 5 stars	$23.96 -3.7%	$34.60 +44.4%	N/A	$1.33B	$6.50M	N/A	76	News Coverage Analyst Downgrade
XNCR Xencor	2.7111 of 5 stars	$18.81 +7.7%	$24.25 +28.9%	+110.4%	$1.30B	$125.58M	N/A	280	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AKBA) was last updated on 7/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Akebia Therapeutics (AKBA) Competitors

AKBA vs. NNNN, PAHC, AKTS, XNCR, and IMTX

How does Akebia Therapeutics compare to Anbio Biotechnology?

Summary

How does Akebia Therapeutics compare to Phibro Animal Health?

Summary

How does Akebia Therapeutics compare to Aktis Oncology?

Summary

How does Akebia Therapeutics compare to Xencor?

Summary

How does Akebia Therapeutics compare to Immatics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA vs. The Competition

Akebia Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Akebia Therapeutics (AKBA) Competitors

AKBA vs. NNNN, PAHC, AKTS, XNCR, and IMTX

How does Akebia Therapeutics compare to Anbio Biotechnology?

Is AKBA or NNNN more profitable?

Do analysts prefer AKBA or NNNN?

Which has stronger earnings & valuation, AKBA or NNNN?

Do insiders and institutionals have more ownership in AKBA or NNNN?

Which has more risk and volatility, AKBA or NNNN?

Does the media refer more to AKBA or NNNN?

Summary

How does Akebia Therapeutics compare to Phibro Animal Health?

Do analysts recommend PAHC or AKBA?

Does the media prefer PAHC or AKBA?

Which has more volatility & risk, PAHC or AKBA?

Is PAHC or AKBA more profitable?

Which has higher valuation and earnings, PAHC or AKBA?

Do institutionals & insiders have more ownership in PAHC or AKBA?

Summary

How does Akebia Therapeutics compare to Aktis Oncology?

Do institutionals & insiders believe in AKBA or AKTS?

Which has better valuation and earnings, AKBA or AKTS?

Do analysts rate AKBA or AKTS?

Is AKBA or AKTS more profitable?

Does the media refer more to AKBA or AKTS?

Summary

How does Akebia Therapeutics compare to Xencor?

Do institutionals & insiders hold more shares of AKBA or XNCR?

Is AKBA or XNCR more profitable?

Do analysts rate AKBA or XNCR?

Which has stronger earnings & valuation, AKBA or XNCR?

Which has more risk and volatility, AKBA or XNCR?

Does the media refer more to AKBA or XNCR?

Summary

How does Akebia Therapeutics compare to Immatics?

Does the media refer more to AKBA or IMTX?

Do insiders & institutionals believe in AKBA or IMTX?

Which has more volatility & risk, AKBA or IMTX?

Is AKBA or IMTX more profitable?

Do analysts prefer AKBA or IMTX?

Which has preferable valuation and earnings, AKBA or IMTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA vs. The Competition

Akebia Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools